Acute myocardial infarction
Conditions
Interventions
treatment group:compound Danshen dripping pills
control group:placebo
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years, gender is not limited; 2. According to the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2019), the patient was diagnosed with acute anterior ST-segment elevation myocardial infarction; 3. Primary acute myocardial infarction; 4. PCI reperfusion therapy was completed within 12 hours after onset; 5. Killip is graded between grade I and Grade III; 6. Subjects voluntarily participated in this study and have signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Previous cardiac insufficiency due to other diseases (valvular heart disease, congenital heart disease, pericardial disease, arrhythmia, other non-cardiac causes); 2. The patient underwent CABG surgery within 12 weeks; 3. Patients undergoing cardiac resynchronization therapy; 4. Patients with left ventricular outflow tract obstruction; 5. Complicated with myocarditis; 6. Uncontrolled severe arrhythmia; 7. Combined aortic aneurysm; 8. Complicated with severe liver, kidney, hematological, mental or systemic diseases; 9. Significant hepatic and renal insufficiency (ALT 2.0 upper limit of normal; Serum creatinine > 1.5 times the upper limit of normal); 10. Serum potassium > 5.5mmol/L; 11. Uncontrolled hypertension (higher than 180/110mmHg); 12. Pregnant or lactating patients; 13. Allergic to compound Danshen dripping pills; 14. Participate in clinical research of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ejection fraction;Myocardial strain rate;NT-proBNP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac event; | — |
Countries
China
Contacts
Public ContactLu Yuan
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed